Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyCHRS +0.40%42 Net Current Asset Value is $0.02 as of Jun. 2026, which is 100% below its 10-year median of 20.00. GuruFocus rates CHRS with a GF Score™ of 42/100 and a GF Value™ of $0.94 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 936 Biotechnology companies, Coherus Oncology ranks worse than 75.53% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Coherus Oncology's net current asset value per share for the quarter that ended in Jun. 2026 was $0.02.
The historical rank and industry rank for Coherus Oncology's Net Current Asset Value or its related term are showing as below:
CHRS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.41 Med: 20 Max: 825
Current: 63.5
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Coherus Oncology was 825.00. The lowest was 1.41. And the median was 20.00.
CHRS's Price-to-Net-Current-Asset-Value is ranked worse than 75.53% of 936
companies
in the Biotechnology industry
Industry Median: 4.745
vs CHRS: 63.50
Coherus Oncology (NAS:CHRS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Coherus Oncology Net Current Asset Value Related Terms
Coherus Oncology Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHRS vs NAUT, AVXL, SLNCF: Net Current Asset Value Comparison
For the Biotechnology subindustry, Coherus Oncology's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.02 mean?
Coherus Oncology (CHRS) has a Net Current Asset Value of $0.02 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Coherus Oncology and its competitors. This is 100% below median its historical median of 20.00. Over the past decade, Coherus Oncology's Net Current Asset Value has ranged from 1.41 to 825.00. According to the industry distribution chart, Coherus Oncology ranks #707 out of 936 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Coherus Oncology's Net Current Asset Value too high?
Coherus Oncology's current Net Current Asset Value of $0.02 is 100% below median its 10-year median of 20.00. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 825.00. The Biotechnology industry median Net Current Asset Value is 4.75. Coherus Oncology's value of $0.02 is 99.6% below this industry median. Based on the distribution chart, Coherus Oncology ranks #707 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Net Current Asset Value compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #707 out of 936 companies for Net Current Asset Value. This places Coherus Oncology in the lower half of its industry. The industry median Net Current Asset Value is 4.75. Coherus Oncology's value of $0.02 is 99.6% below this benchmark. Historically, Coherus Oncology's own Net Current Asset Value has ranged from 1.41 to 825.00 over the past decade. While the company's 10-year median is 20.00 vs. the industry median of 4.75, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.75, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Net Current Asset Value of $0.02 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Net Current Asset Value is $0.02, which is 100% below median its own 10-year median of 20.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.94, compared to a current price of $1.27 — trading 35.1% above its estimated fair value. The current Net Current Asset Value is $0.02, which is 100% below median its 10-year median of 20.00 and 99.6% below the Biotechnology industry median of 4.75. Coherus Oncology's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current Net Current Asset Value is $0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (CHRS) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of $1.27 is trading 35.1% above its estimated GF Value™ of $0.94.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for CHRS:
Net Current Asset Value: $0.02 (100% below median its 10-year median of 20.00)
GF Value™: $0.94 vs. price of $1.27 (35.1% above fair value)
Industry Position: 99.6% below the Biotechnology median (#707 of 936)
No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score
Get the complete analysis for CHRS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHRS has been successfully added to your 
